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Background: Research has shown that hepatitis B virus (HBV) genotypes are closely linked to
the  clinical manifestations, treatment, and prognosis of the disease.
Objective: To study the association between genotype and drug-resistant HBV mutations in
620  Chinese patients with chronic HBV infection.
Methods: HBV DNA levels were determined using real-time quantitative PCR in plasma sam-
ples. Microarrays were performed for the simultaneous detection of HBV genotypes (HBV/B,
C,  and D) and drug-resistance-related hotspot mutations. A portion of the samples analyzed
using  microarrays was selected randomly and the data were conﬁrmed using direct DNA
sequencing.
Results: Most samples were genotype C (471/620; 76.0%), followed by genotype B (149/620;
24.0%). Among the 620 patient samples, 17 (2.7%) had nucleotide analogs (NA) resistance-
related mutations. Of these, nine and eight patients carried lamivudine (LAM)-/telbivudine
(LdT)-resistance mutations (rtL180M, rtM204I/V) and adefovir (ADV)-resistance mutations
(rtA181T/V, rtN236T), respectively. No patients had both lamivudine (LAM)- and either ade-
fovir (ADV) or entecavir (ETV) resistance mutations. Additionally, out of the 620 patient
samples, 64.0% (397/620) were also detected with the precore stop-codon mutation (G1896A)
by  microarray assay.
Conclusion: The results of the current study revealed that the prevalence of nucleotide
analogs (NA)-resistance in Chinese hospitalized HBV-positive patients was so low that inten-
sive nucleotide analogs (NA)-resistance testing before nucleotide analog (NA) treatment
might not be required. In addition, the present study suggests that chronic HBV patients withgenotype C were infected with ﬁtter viruses and had an increased prevalence of nucleotide
analogs (NA)-resistance mutations compared to genotype B virus.
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DNA levels using real-time quantitative PCR. In addition,
serum samples were used to determine the HBV genotypes
and drug resistance-related mutations.
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Fig. 1 – Microarray-based HBV genotyping and drug
resistance-related mutations. (A) Layout of the microarray
used in the current study. All probes, with the exception of
QC and PC, were  spotted in three replicates; QC  and PC
were  spotted in six replicates. QC and BC were  the positive
and negative controls for array production, respectively. PC
and NC were the positive and negative controls for
hybridization, and IC1 and IC2 were  the internal controls
for HBV ampliﬁcation, respectively. B, C, and D represent
HBV genotypes B, C, and D, respectively. 180M, 181T/V,
204I/V, and 236T represent the rtL180M, rtA181T/V,
rtM204I/V, and rtN236T, respectively, mutations in the HBV
reverse transcriptase region. 1896A denotes the G1896A292  b r a z j i n f e c t d 
Introduction
Hepatitis B virus (HBV) infection is a major global health prob-
lem that affects more  than 240 million people worldwide,
causing more  than 780,000 deaths annually.1 Therefore, it is
becoming increasingly important to take effective measures
to control the incidence of HBV in China.
The HBV genotype has formed over a long period, during
which point mutations have accumulated due to the asymme-
try of HBV reverse transcription and its lack of proofreading
enzymes. The HBV mutation rate is high, and the HBV geno-
type reﬂects the natural accumulation of mutations as a result
of virus evolution. HBV can be divided into several genotypes
according to sequence heterogeneity greater than 8%. There
are currently eight HBV genotypes (A–H) that have a distinctive
geographical distribution and ethnic associations.2 For exam-
ple, genotypes B and C are highly prevalent in Southeast Asia
including China, genotype A is frequent in northwest Europe,
and genotype D is common in the Mediterranean region and
Central Asia.3 A previous retrospective study revealed that
HBV genotype B was associated with earlier HBeAg serocon-
version than was genotype C.4 When receiving interferon (IFN)
therapy, patients with HBV genotype B have a higher rate
of IFN-induced HBeAg clearance compared with those with
genotype C.5
In addition to IFN, nucleotide analogs (NAs) are also cur-
rently approved for the treatment of HBV infection. NAs inhibit
HBV replication and reduce the damage to hepatocytes by
competing for incorporation into the viral DNA strands.6 Four
NAs have been licensed for clinical use in China: lamivudine
(LAM), adefovir (ADV), entecavir (ETV), and telbivudine (LdT).
However, long-duration NA treatment increases the preva-
lence of resistant HBV and leads to treatment failure. For
example, LAM, the ﬁrst widely used antiviral NA, results in
a cumulative incidence of resistance as high as 70% after ﬁve
years of treatment.7 The resistance-related mutations are usu-
ally located in the reverse transcriptase region of the HBV
polymerase gene.8 The classical LAM-/LdT-resistance muta-
tions are rtM204I and rtM204V.9,10 Of these, rtL180M is a
compensatory mutation that often coexists with rtM204I/V
to restore viral replication efﬁcacy.11 In addition, rtN236T and
rtA181V are well-recognized ADV-resistance mutations.12 The
most prevalent mutation in the precore region (G1896A) cre-
ates a TAG stop codon that abolishes the synthesis of HBeAg;
thus, the dominance of this mutation could easily account for
HBeAg seronegativity.13
The aim of the current study was to determine the
HBV genotypes and drug resistance-related mutations in 620
clinical samples simultaneously using microarrays to better
understand the correlation between HBV genotypes and drug-
resistant mutations.
Materials  and  methodsPatient  samples
A total of 620 patients consisting of 286 males and 334 females
with chronic HBV infection were enrolled in the study in 1 5;1  9(3):291–295
Beijing Ditan Hospital. The ages of these patients ranged
from one month to 80 years, with a mean of 33.7 ± 12.2 years.
Among the 620 patients, 271 received NA-based therapy, 35
received IFN-based therapy, eight received the combination
therapy of NA and IFN, and the other 306 were NA/IFN naïve.
Informed consent was obtained from adult patients or the
guardians of minor patients at the time of whole blood col-
lection for the purpose of HBV testing. The plasma samples
obtained from whole blood were used to determine the HBVmutation in the HBV precore region. (B) Hybridization
results of the classical HBV samples with genotypes B and
C. (C) Hybridization results of eight classical NA-resistant
samples.
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Table 1 – HBV genotyping results of the 620 patient
samples.
Gender HBV/B (%) HBV/C (%) Total
Male 68 (23.8%) 218 (76.2%) 286
Female 81 (24.3%) 253 (75.7%) 334b r a z j i n f e c t d i s .
uantiﬁcation  of  HBV  DNA
BV DNA was quantiﬁed using a Cobas AmpliPrep/Cobas
aqman (CAP/CTM) platform (Roche Molecular Systems,
leasanton, CA, USA). HBV DNA was extracted from 1-mL
lasma using a Cobas AmpliPrep automated extractor accord-
ng to the manufacturer’s instructions. The Cobas Taqman 48
nalyzer was used for automated real-time PCR ampliﬁcation
nd the detection of PCR products according to the manufac-
urer’s instructions. HBV DNA levels were expressed as IU/mL.
BV  DNA  genotyping  and  drug-resistance-related
utation  analysis
BV DNA was extracted from 200-L serum samples using
 Magbind CFDNA kit (KWBiotech, Beijing, China). Multi-
lex PCR, microarray hybridization, and microarray scanning
ere conducted as recommended by the manufacturer of the
icroarray kit (CapitalBio Corporation, Beijing, China) for the
imultaneous detection of the HBV genotypes (HBV/B, C, and
) and drug-resistance-related hotspot mutations (rtL180M,
tA181T/V, rtM204I/V, rtN236T in the HBV reverse transcrip-
ase region, and G1896A in the HBV precore region). The
ecommended genotype and mutation-related allele-speciﬁc
rimers were used for multiplex PCR. After ampliﬁcation, the
eaction mixture was hybridized with probes immobilized on
he microarray chip at 50 ◦C for 60 min. Subsequently, the
icroarray chip was washed in washing buffer (0.1% SDS and
.3× SSC) at 42 ◦C for 2 min. The chips were scanned and
maged using a microarray Scanner LuxScanTM10K-B (Capital-
io). Assay results were determined based on the ﬂuorescent
ybridization signal and distribution of the microarray probes.
he microarray probes corresponding to HBV genotypes and
rug-resistance-related mutations are shown in Fig. 1A.
BV  DNA  sequencing
he results of HBV DNA genotyping and drug-resistance-
elated mutations obtained from the microarrays for a random
election of samples were further conﬁrmed using direct DNA
equencing with the BigDye Terminator v3.1 Cycle Sequencing
it and an ABI 3730 DNA analyzer (Applied Biosystems, Foster
ity, CA). The primer sequences and PCR ampliﬁcation con-
itions used for direct DNA sequencing have been described
lsewhere.14–16
tatistical  analysis
tatistical analysis was performed using the SPSS 17.0 soft-
are package. All values in the text and ﬁgures are expressed
s the mean ± standard deviation (SD) of these observations.
esults
BV  DNA  quantiﬁcationhe HBV DNA levels in the 620 enrolled samples ranged from
.00E5 to 1.50E9 IU/mL, with a mean of 9.89E6 IU/mL (see Sup-
lementary Table S1), as determined by real-time quantitativeTotal 149 (24.0%) 471 (76.0%) 620
PCR. The results also conﬁrmed that all studied clinical sam-
ples were HBV-positive.
Supplementary Table S1 related to this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.bjid.
2015.03.012.
HBV  DNA  genotypes
Two HBV genotypes (B and C) were detected among the 620
HBV DNA positive samples using the Capitalbio microarray
assay, as shown in Supplementary Table S1. The microarray
hybridization results for the HBV genotypes B and C are shown
in Fig. 1B. Of these, 44 samples with genotype B and 151 sam-
ples with genotype C were selected randomly and the results
were validated using direct DNA sequencing. As shown in
Table 1, most samples were identiﬁed as genotype C, 471/620
(76.0%), followed by genotype B, 149/620 (24.0%).
Drug  resistance-related  mutations
By microarray assay, NA resistance-related mutational pat-
terns of the 620 patient samples were also directly acquired
from hybridization results, as shown in Supplementary Table
S1. The mutation patterns of 211 patient samples were then
selected and further conﬁrmed using direct DNA sequencing.
Among the 620 patient samples, 17 (17/620; 2.7%) carried NA
resistance-related mutations, as showed in Table 2 and Fig. 1C.
The mean age of these 17 patients was 47.7 ± 12.5 years, which
was higher than that of the 620 patients (33.7 ± 12.2). Most
of the 17 patient samples belonged to genotype C (14/17,
82.4%), and the remaining to genotype B (3/17, 17.6%). Among
the 17 patients, nine carried LAM-/LdT-resistance mutations
(rtL180M, rtM204I/V), and eight had ADV-resistance muta-
tions (rtA181T/V, rtN236T). The most common mutations
in the LAM-resistant patients were rtM204I and rtM204V,
which were found in 35.3% (6/17) of the 17 NA-resistant
patients. The compensatory mutation rtL180M was simul-
taneously detected with rtM204I/V in 17.6% (3/17). The
ADV-resistance mutations rtA181V and rtN236T were found
in 29.4% (5/17) of these patients. No patient samples with
LAM and ADV or ETV-resistance mutations were detected.
Among the 17 patients, 4 carried NA-resistance mutations
but were NA/IFN-naïve. Ten carried NA-resistance mutations
and the NA/IFN-based therapeutic strategy adopted previously
was appropriate and effective. The remaining three patients
also carried NA-resistance mutations but the previous NA/IFN
therapy was not effective and led to treatment failure and
was altered. More speciﬁcally, patients P119 and P287 both
carried rtA181V but received ADV/IFN, P217 carried rtM204I
but received LdT. In addition, the microarrays revealed that
397 (64.0%) of the 620 patient samples also carried the precore
294  b r a z j i n f e c t d i s . 2 0 1 5;1  9(3):291–295
Table 2 – Assay results of the 17 NA-resistance samples.
Sample ID Gender Age NA-resistance Genotype G1896A HBV treatment
P51 Male 45 rtL180M, rtM204I HBV/C A Naïve
P103 Male 52 rtL180M, rtM204V HBV/C G LAM + ADV
P119 Male 48 rtA181V HBV/C G ADV
P160 Male 43 rtN236T HBV/B A Naïve
P163 Male 48 rtL180M HBV/C A Naïve
P208 Male 50 rtM204I HBV/C A ETV
P217 Female 57 rtM204I HBV/C A LdT
P227 Female 52 rtM204I HBV/C A ETV
P250 Female 35 rtL180M, rtM204I HBV/C A LAM + ADV
P279 Female 33 rtA181T HBV/C G LdT + ADV
P287 Female 32 rtA181V HBV/C A IFN
P304 Male 74 rtL180M HBV/B A ETV
P393 Male 74 rtL180M HBV/B A ETV
P429 Female 53 rtN236T HBV/C G ETV
P487 Female 37 rtA181T HBV/C G ETV
 
 
rP564 Male 45 rtA181T
P600 Male 34 rtN236T
stop-codon mutation (G1896A), and this was conﬁrmed in 197
samples using direct DNA sequencing.
Discussion
Most of the samples analyzed in the current study belonged to
genotype C (471/620; 76.0%) followed by genotype B (149/620;
24.0%). Moreover, there were no marked differences in the
distribution of genotypes B and C between male and female
patients. These data are consistent with a previous report
from northern China, where 78% of the studied HBsAg carri-
ers were infected with genotype C, and 22% carried genotype
B.14 However, genotype D was not observed among the patient
samples studied. Interestingly, previous reports also identiﬁed
HBV genotype D in only northwestern China.17,18
In the current study, 17 patients (17/620; 2.7%) carried
NA-resistance-related mutations. These data are consistent
with a previous report that preexisting NA-resistance-related
mutations were detected in 2.01% of NA-naïve Chinese HBV-
infected patients.19 These results suggest that the incidence of
NA-resistance in Chinese hospitalized HBV-positive patients
is so low that intensive testing for NA-resistance before
treatment might not be required, consistent with a previous
suggestion.19 In most cases in the current study, NA-resistance
mutations were derived from either naturally occurring viral
mutations or were transmitted from drug-resistant patients.
However, the 17 patients had a mean age of 47.7 ± 12.5 years,
which was higher than the mean age of the 620 patients
(33.7 ± 12.2). This suggests that the 17 NA-resistance patients
had an increased likelihood of being treated using antiviral
therapy; therefore, NA resistance testing might be more  nec-
essary for HBV-positive elderly patients.
Most of the 17 patients samples belong to genotype C
(14/17, 82.4%), and the remaining to genotype B (3/17, 17.6%).
The proportion of genotype C in the 17 NA-resistance patients
was considerably higher than the above-mentioned data
(76.0%) in the 620 HBV-positive patients. These data suggest
that HBV patients with genotype C were infected with ﬁtter
viruses, which facilitated acquisition of NA-resistance muta-
tions, compared with those with genotype B.HBV/C G ETV + IFN
HBV/C A Naïve
The mutations rtM204I and rtM204V were the most fre-
quent mutations in the LAM-resistant patients, being detected
in 35.3% (6/17). The compensatory mutation rtL180M was
detected simultaneously with rtM204I/V in 17.6% (3/17) of the
patients. The ADV-resistance mutations rtA181V and rtN236T
were found in 29.4% (5/17) of the patients. LAM and ADV dual
resistance was not detected in any of the 17 patients. Long-
term use of NA might have led to multidrug resistance.20
Therefore, NA resistance testing becomes increasingly neces-
sary. For patients P119, P217 and P287 of the 17 patients, the
results of NA resistance testing implied in advance that the
used NA/IFN therapeutic strategies would lead to treatment
failure and had to be altered. It showed that NA resistance
testing may be necessary when deciding for the NA/IFN ther-
apeutic strategy.
Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
Acknowledgements
We are grateful to Guotong Yin and Yunlong Hao (Capitalbio)
for their excellent technical assistance. We are also grateful
to Dr. Yingying Liu (Capitalbio) for helpful discussions and
support.
 e  f  e  r  e  n  c  e  s
1. World Health Organization. Hepatitis B fact sheets; 2012.
Available from:
http://www.who.int/mediacentre/factsheets/fs204/en/
[updated July 2014].
2. Bartholomeusz A, Schaefer S. Hepatitis B virus genotypes:
comparison of genotyping methods. Rev Med Virol.
2004;14:3–16.3. Miyakawa Y, Mizokami M. Classifying hepatitis B virus
genotypes. Intervirology. 2003;46:329–38.
4. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is
associated with earlier HBeAg seroconversion compared with
 2 0 1 
1
1
1
1
1
1
1
1
1
1b r a z j i n f e c t d i s .
hepatitis B virus genotype C. Gastroenterology.
2002;122:1756–62.
5. Wai CT, Chu CJ, Hussain M, et al. HBV genotype B is
associated with better response to interferon therapy in
HBeAg (+) chronic hepatitis than genotype C. Hepatology.
2002;36:1425–30.
6. Nebbia G, Peppa D, Maini MK. Hepatitis B infection: current
concepts and future challenges. Q J Med. 2012;105:109–13.
7. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant
HBV: standardization of nomenclature and assays and
recommendations for management. Hepatology.
2007;46:254–65.
8. Wang F, Wang H, Shen H, et al. Evolution of hepatitis B virus
polymerase mutations in a patient with HBeAg-positive
chronic hepatitis B virus treated with sequential
monotherapy and add-on nucleoside/nucleotide analogues.
Clin Ther. 2009;31:360–6.
9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009.
Hepatology. 2009;50:661–2.
0. Tillmann HL, McHutchison JG. Telbivudine versus lamivudine
in  patients with chronic hepatitis B. N Engl J Med.
2008;358:1517–8.
1. Yuen LK, Locarnini SA. Genetic variability of hepatitis B virus
and response to antiviral treatments: searching for a bigger
picture. J Hepatol. 2009;50:445–8.
2. Borroto-Esoda K, Miller MD, Arterburn S. Pooled analysis of
amino acid changes in the HBV polymerase in patients from
25;1 9(3):291–295 295
four major adefovir dipivoxil clinical trials. J Hepatol.
2007;47:492–8.
3. Nie H, Evans AA, London WT, et al. Quantitative dynamics of
hepatitis B basal core promoter and precore mutants before
and after HBeAg seroconversion. J Hepatol. 2012;56:795–802.
4. Yuan J, Zhou B, Tanaka Y, et al. Hepatitis B virus (HBV)
genotypes/subgenotypes in China: mutations in core
promoter and precore/core ad their clinical implications. J
Clin Virol. 2007;39:87–93.
5. Han Y, Huang LH, Liu CM, et al. Characterization of hepatitis B
virus reverse transcriptase sequences in Chinese treatment
naive patients. J Gastroenterol Hepatol. 2009;24:1417–23.
6. Zoulim F, Locarnini S. Hepatitis B virus resistance to
nucleos(t)ide analogues. Gastroenterology. 2009;137:
1593–608.
7. Wang Z, Huang Y, Wen S, et al. Hepatitis B virus genotypes
and subgenotypes in China. Hepatol Res. 2007;37:S36–41.
8. Zeng G, Wang Z, Wen S, et al. Geographic distribution,
virologic and clinical characteristics of hepatitis B virus
genotypes in China. J Viral Hepat. 2005;12:609–17.
9. Li X, Liu Y, Zhao P, et al. Investigation into drug-resistant
mutations of HBV from 845 nucleoside analogue-naïve
Chinese patients with chronic HBV infection. Antivir Ther.
2015;20(2):141–7.
0. Song ZL, Cui YJ, Zheng WP, et al. Diagnostic and therapeutic
progress of multi-drug resistance with anti-HBV nucleotide
analogues. World J Gastroenterol. 2012;18:7149–57.
